Vineeth Kumar, Resident in Medical Oncology at AIIMS New Delhi, shared a post on X:
“Presented our study in CTOS 2025 as poster!
Highlights
Phase II High-Dose Ifosfamide (HD-IFO) in Metastatic/Unresectable Synovial Sarcoma
Prospective single-arm study from a tertiary sarcoma center.
N = 25 translocation-positive patients.
Dose and Regimen
HD-Ifosfamide was given at:
- 11 g/m² per cycle
- Planned 6 cycles in total.
- Primary endpoint: ORR at 4 cycles.
- Secondary: PFS and OS.
Patient Characteristics
- Median age 30 years (16–50)
- ECOG 0–1: 65%
- Median prior lines: 1 (range 1–6)
- Prior surgery 83%
- Prior radiation 70%
- Prior ifosfamide–doxorubicin 78%
- Pazopanib 43%
Efficacy (RECIST 1.1, N = 20 evaluable)
- PR: 13 (65%)
- SD: 3 (15%)
- PD: 4 (25%)
- ORR 65%
- DCR 80%
Waterfall plot shows consistent deep tumor shrinkage.
Survival Outcomes
- Median PFS: 9.2 months (95% CI: 6.5–12)
- OS not reached (follow-up ongoing)
HD-IFO consistently produced early partial responses with durable benefit.
Toxicity Profile
- Grade 3–4 neutropenia 52%
- Grade 3–4 anemia 40%
- Grade 3 thrombocytopenia 15%
One early death from grade 4 encephalopathy.
Takeaway
High-dose Ifosfamide at 11 g/m² is one of the most active and reliable regimens in advanced synovial sarcoma—delivering deep and durable responses even in previously treated patients.”
More posts about CTOS 2025.
